Abiraterone
The serum concentration of Artemether can be increased when it is combined with Abiraterone.
Acepromazine
The serum concentration of Acepromazine can be increased when it is combined with Artemether.
Aceprometazine
The serum concentration of Aceprometazine can be increased when it is combined with Artemether.
Advertisement
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Artemether.
Acetylcholine
The metabolism of Acetylcholine can be decreased when combined with Artemether.
Acetylcholine Chloride
The metabolism of Acetylcholine can be decreased when combined with Artemether.
Advertisement
Ajmaline
The metabolism of Ajmaline can be decreased when combined with Artemether.
Albuterol
Salbutamol may increase the QTc-prolonging activities of Artemether.
Alfuzosin
Alfuzosin may increase the QTc-prolonging activities of Artemether.
Advertisement
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Artemether.
Alogliptin
The metabolism of Alogliptin can be decreased when combined with Artemether.
Alprenolol
The metabolism of Alprenolol can be decreased when combined with Artemether.
Amantadine
Amantadine may increase the QTc-prolonging activities of Artemether.
Aminopyrine
The metabolism of Aminophenazone can be decreased when combined with Artemether.
Amiodarone
The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Artemether.
Amitriptyline
Amitriptyline may increase the QTc-prolonging activities of Artemether.
Amlodipine
The therapeutic efficacy of Artemether can be increased when used in combination with Amlodipine.
Amodiaquine
The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Artemether.
Amoxapine
Amoxapine may increase the QTc-prolonging activities of Artemether.
Amphetamine
The metabolism of Amphetamine can be decreased when combined with Artemether.
Amphotericin B
The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.
amphotericin B liposomal
The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.
Amprenavir
The metabolism of Amprenavir can be decreased when combined with Artemether.
Amsacrine
The metabolism of Amsacrine can be decreased when combined with Artemether.
Anagrelide
The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Artemether.
Anhydrous Tacrolimus
The metabolism of Tacrolimus can be decreased when combined with Artemether.
Antipyrine
The metabolism of Antipyrine can be decreased when combined with Artemether.
Apalutamide
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Apalutamide resulting in a loss in efficacy.
Apomorphine
Apomorphine may increase the QTc-prolonging activities of Artemether.
Aprepitant
The serum concentration of Artemether can be increased when it is combined with Aprepitant.
Aprindine
The metabolism of Aprindine can be decreased when combined with Artemether.
Arformoterol
Arformoterol may increase the QTc-prolonging activities of Artemether.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Artemether.
Armodafinil
The metabolism of Artemether can be decreased when combined with Armodafinil.
Arsenic Trioxide
The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Artemether.
Artesunate
The risk or severity of QTc prolongation can be increased when Artesunate is combined with Artemether.
Asenapine
The risk or severity of QTc prolongation can be increased when Asenapine is combined with Artemether.
Astemizole
The metabolism of Astemizole can be decreased when combined with Artemether.
Atazanavir
The metabolism of Artemether can be decreased when combined with Atazanavir.
Atomoxetine
Atomoxetine may increase the QTc-prolonging activities of Artemether.
Atovaquone
The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether.
Azelastine
The metabolism of Azelastine can be decreased when combined with Artemether.
Azithromycin
Azithromycin may increase the QTc-prolonging activities of Artemether.
Bedaquiline
Bedaquiline may increase the QTc-prolonging activities of Artemether.
Bencyclane
The therapeutic efficacy of Artemether can be increased when used in combination with Bencyclane.
Benztropine
The metabolism of Benzatropine can be decreased when combined with Artemether.
Benzyl Alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Artemether.
Bepridil
The metabolism of Bepridil can be decreased when combined with Artemether.
Betaxolol
The metabolism of Betaxolol can be decreased when combined with Artemether.
Bisoprolol
The metabolism of Bisoprolol can be decreased when combined with Artemether.
Boceprevir
The metabolism of Artemether can be decreased when combined with Boceprevir.
Bortezomib
Bortezomib may increase the QTc-prolonging activities of Artemether.
Bosentan
The serum concentration of Artemether can be decreased when it is combined with Bosentan.
Brexpiprazole
The serum concentration of Brexpiprazole can be increased when it is combined with Artemether.
Brompheniramine
The metabolism of Brompheniramine can be decreased when combined with Artemether.
Bupivacaine
The metabolism of Bupivacaine can be decreased when combined with Artemether.
Buprenorphine
The metabolism of Buprenorphine can be decreased when combined with Artemether.
Bupropion
The metabolism of Artemether can be decreased when combined with Bupropion.
Buserelin
Buserelin may increase the QTc-prolonging activities of Artemether.
Buspirone
The metabolism of Buspirone can be decreased when combined with Artemether.
Busulfan
The serum concentration of Busulfan can be increased when it is combined with Artemether.
Caffeine
The metabolism of Caffeine can be decreased when combined with Artemether.
Capecitabine
The metabolism of Artemether can be decreased when combined with Capecitabine.
Captopril
The metabolism of Captopril can be decreased when combined with Artemether.
Carbamazepine
The metabolism of Artemether can be increased when combined with Carbamazepine.
Cariprazine
The metabolism of Cariprazine can be decreased when combined with Artemether.
Carteolol
The metabolism of Carteolol can be decreased when combined with Artemether.
Carvedilol
The metabolism of Carvedilol can be decreased when combined with Artemether.
Celecoxib
The metabolism of Artemether can be decreased when combined with Celecoxib.
Cephalexin
The metabolism of Cephalexin can be decreased when combined with Artemether.
CEPHALEXIN ANHYDROUS
The metabolism of Cephalexin can be decreased when combined with Artemether.
Ceritinib
The serum concentration of Artemether can be increased when it is combined with Ceritinib.
Cevimeline
The metabolism of Cevimeline can be decreased when combined with Artemether.
Chloramphenicol
The metabolism of Artemether can be decreased when combined with Chloramphenicol.
Chlordiazepoxide
The metabolism of Chlordiazepoxide can be decreased when combined with Artemether.
Chloroquine
The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Artemether.
Chlorotrianisene
The serum concentration of Chlorotrianisene can be decreased when it is combined with Artemether.
Chlorpheniramine
The metabolism of Chlorphenamine can be decreased when combined with Artemether.
CHLORPHENIRAMINE POLISTIREX
The metabolism of Chlorphenamine can be decreased when combined with Artemether.
Chlorpromazine
Chlorpromazine may increase the QTc-prolonging activities of Artemether.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Artemether.
Cholecalciferol
The metabolism of Artemether can be decreased when combined with Cholecalciferol.
Cilostazol
The metabolism of Cilostazol can be decreased when combined with Artemether.
Cimetidine
The metabolism of Artemether can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Artemether can be decreased when combined with Cinacalcet.
Cinnarizine
The metabolism of Cinnarizine can be decreased when combined with Artemether.
Ciprofloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Artemether.
Cisapride
The serum concentration of Cisapride can be increased when it is combined with Artemether.
Citalopram
The metabolism of Artemether can be decreased when combined with Citalopram.
Clarithromycin
Clarithromycin may increase the QTc-prolonging activities of Artemether.
Clemastine
The metabolism of Artemether can be decreased when combined with Clemastine.
Clevidipine
The metabolism of Clevidipine can be decreased when combined with Artemether.
Clevidipine butyrate
The metabolism of Clevidipine can be decreased when combined with Artemether.
Clobazam
The metabolism of Artemether can be decreased when combined with Clobazam.
Clomipramine
Clomipramine may increase the QTc-prolonging activities of Artemether.
Clonidine
The metabolism of Clonidine can be decreased when combined with Artemether.
Clopidogrel
The metabolism of Artemether can be decreased when combined with Clopidogrel.
Clotrimazole
The metabolism of Artemether can be decreased when combined with Clotrimazole.
Clozapine
Clozapine may increase the QTc-prolonging activities of Artemether.
Cobicistat
The serum concentration of Artemether can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Artemether can be decreased when combined with Cocaine.
Codeine
The therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.
Codeine Anhydrous
The therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.
CODEINE POLISTIREX
The therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Artemether.
Crisaborole
The metabolism of Artemether can be decreased when combined with Crisaborole.
Crizotinib
Crizotinib may increase the QTc-prolonging activities of Artemether.
Cyclandelate
The therapeutic efficacy of Artemether can be increased when used in combination with Cyclandelate.
Cyclobenzaprine
The metabolism of Cyclobenzaprine can be decreased when combined with Artemether.
Cyclophosphamide
The metabolism of Cyclophosphamide can be decreased when combined with Artemether.
Cyclophosphamide Anhydrous
The metabolism of Cyclophosphamide can be decreased when combined with Artemether.
Cyclosporine
The metabolism of Cyclosporine can be decreased when combined with Artemether.
Dabrafenib
The serum concentration of Artemether can be decreased when it is combined with Dabrafenib.
Dapagliflozin
The metabolism of Dapagliflozin can be decreased when combined with Artemether.
Dapsone
The risk or severity of adverse effects can be increased when Artemether is combined with Dapsone.
Darifenacin
The metabolism of Artemether can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Artemether can be increased when it is combined with Darunavir.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Artemether.
Dasatinib
The serum concentration of Artemether can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Artemether can be increased when it is combined with Dasatinib.
Debrisoquin
The metabolism of Debrisoquin can be decreased when combined with Artemether.
Deferasirox
The serum concentration of Artemether can be decreased when it is combined with Deferasirox.
Degarelix
Degarelix may increase the QTc-prolonging activities of Artemether.
Delavirdine
The metabolism of Artemether can be decreased when combined with Delavirdine.
Desflurane
Desflurane may increase the QTc-prolonging activities of Artemether.
Desipramine
Desipramine may increase the QTc-prolonging activities of Artemether.
Desogestrel
The serum concentration of Desogestrel can be decreased when it is combined with Artemether.
Deutetrabenazine
The metabolism of Deutetrabenazine can be decreased when combined with Artemether.
Dexchlorpheniramine maleate
The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Artemether.
Dexfenfluramine
The metabolism of Dexfenfluramine can be decreased when combined with Artemether.
Dexmethylphenidate
The metabolism of Dexmethylphenidate can be decreased when combined with Artemether.
Dextroamphetamine
The metabolism of Dextroamphetamine can be decreased when combined with Artemether.
Dextromethorphan
The metabolism of Dextromethorphan can be decreased when combined with Artemether.
Didanosine
Didanosine can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dienestrol
The serum concentration of Dienestrol can be decreased when it is combined with Artemether.
Dienogest
The serum concentration of Dienogest can be decreased when it is combined with Artemether.
Diethylstilbestrol
The serum concentration of Diethylstilbestrol can be decreased when it is combined with Artemether.
Dihydrocodeine
The metabolism of Dihydrocodeine can be decreased when combined with Artemether.
Dihydroergotamine
The metabolism of Artemether can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Artemether can be decreased when combined with Diltiazem.
Diphenhydramine
Diphenhydramine may increase the QTc-prolonging activities of Artemether.
Disopyramide
The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Artemether.
Docetaxel
The metabolism of Docetaxel can be decreased when combined with Artemether.
DOCETAXEL ANHYDROUS
The metabolism of Docetaxel can be decreased when combined with Artemether.
Dofetilide
The serum concentration of Dofetilide can be increased when it is combined with Artemether.
Dolasetron
Dolasetron may increase the QTc-prolonging activities of Artemether.
Domperidone
The risk or severity of QTc prolongation can be increased when Domperidone is combined with Artemether.
Donepezil
The metabolism of Donepezil can be decreased when combined with Artemether.
Dopamine
The metabolism of Dopamine can be decreased when combined with Artemether.
Dothiepin
The metabolism of Artemether can be decreased when combined with Dosulepin.
Doxazosin
The metabolism of Doxazosin can be decreased when combined with Artemether.
Doxepin
Doxepin may increase the QTc-prolonging activities of Artemether.
Doxorubicin
The metabolism of Doxorubicin can be decreased when combined with Artemether.
Doxorubicin Hydrochloride
The metabolism of Doxorubicin can be decreased when combined with Artemether.
Doxycycline
The risk or severity of QTc prolongation can be increased when Doxycycline is combined with Artemether.
Doxycycline Anhydrous
The risk or severity of QTc prolongation can be increased when Doxycycline is combined with Artemether.
Dronedarone
The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Artemether.
Droperidol
Droperidol may increase the QTc-prolonging activities of Artemether.
Drospirenone
The serum concentration of Drospirenone can be decreased when it is combined with Artemether.
Duloxetine
The metabolism of Artemether can be decreased when combined with Duloxetine.
Efavirenz
The serum concentration of Artemether can be decreased when it is combined with Efavirenz.
Eletriptan
The metabolism of Eletriptan can be decreased when combined with Artemether.
Eliglustat
The serum concentration of Eliglustat can be increased when it is combined with Artemether.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Artemether.
Encainide
The metabolism of Encainide can be decreased when combined with Artemether.
Enzalutamide
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.
Epinastine
The metabolism of Epinastine can be decreased when combined with Artemether.
Eribulin
Eribulin may increase the QTc-prolonging activities of Artemether.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Artemether.
Erythromycin
The metabolism of Artemether can be decreased when combined with Erythromycin.
Escitalopram
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Artemether.
Eslicarbazepine Acetate
The metabolism of Artemether can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Artemether can be decreased when combined with Esomeprazole.
Estradiol
The serum concentration of Estradiol can be decreased when it is combined with Artemether.
Estramustine
The serum concentration of Estramustine can be decreased when it is combined with Artemether.
Estrogens, Conjugated (USP)
The serum concentration of Conjugated estrogens can be decreased when it is combined with Artemether.
Estrogens, Esterified (USP)
The serum concentration of Estrogens, esterified can be decreased when it is combined with Artemether.
Ethinyl Estradiol
The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Artemether.
Ethosuximide
The therapeutic efficacy of Artemether can be increased when used in combination with Ethosuximide.
Ethylmorphine
The metabolism of Ethylmorphine can be decreased when combined with Artemether.
Ethynodiol Diacetate
The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Artemether.
Etonogestrel
The serum concentration of Etonogestrel can be decreased when it is combined with Artemether.
Etoricoxib
The metabolism of Etoricoxib can be decreased when combined with Artemether.
Etravirine
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Etravirine resulting in a loss in efficacy.
Ezogabine
Ezogabine may increase the QTc-prolonging activities of Artemether.
Famotidine
Famotidine may increase the QTc-prolonging activities of Artemether.
Felbamate
Felbamate may increase the QTc-prolonging activities of Artemether.
Felodipine
The therapeutic efficacy of Artemether can be increased when used in combination with Felodipine.
Fendiline
The therapeutic efficacy of Artemether can be increased when used in combination with Fendiline.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Artemether.
Fingolimod
Fingolimod may increase the QTc-prolonging activities of Artemether.
Flecainide
Flecainide may increase the QTc-prolonging activities of Artemether.
Floxuridine
The metabolism of Artemether can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Artemether can be decreased when combined with Fluconazole.
Flunarizine
The metabolism of Flunarizine can be decreased when combined with Artemether.
Fluorouracil
The metabolism of Artemether can be decreased when combined with Fluorouracil.
Fluoxetine
The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Artemether.
Flupenthixol
The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Artemether.
Fluphenazine
The serum concentration of Fluphenazine can be increased when it is combined with Artemether.
Fluspirilene
The therapeutic efficacy of Artemether can be increased when used in combination with Fluspirilene.
Fluvastatin
The metabolism of Fluvastatin can be decreased when combined with Artemether.
Fluvoxamine
The metabolism of Artemether can be decreased when combined with Fluvoxamine.
Formoterol
Formoterol may increase the QTc-prolonging activities of Artemether.
Fosamprenavir
The metabolism of Artemether can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Artemether can be increased when it is combined with Fosaprepitant.
Foscarnet
Foscarnet may increase the QTc-prolonging activities of Artemether.
Fosphenytoin
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Fosphenytoin resulting in a loss in efficacy.
Fusidate
The serum concentration of Artemether can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Artemether can be increased when it is combined with Fusidic Acid.
Gabapentin
The therapeutic efficacy of Artemether can be increased when used in combination with Gabapentin.
Gadobenate
Gadobenic acid may increase the QTc-prolonging activities of Artemether.
Galantamine
Galantamine may increase the QTc-prolonging activities of Artemether.
Gallopamil
The therapeutic efficacy of Artemether can be increased when used in combination with Gallopamil.
Gefitinib
The metabolism of Gefitinib can be decreased when combined with Artemether.
Gemfibrozil
The metabolism of Artemether can be decreased when combined with Gemfibrozil.
Gemifloxacin
Gemifloxacin may increase the QTc-prolonging activities of Artemether.
Gemifloxacin Mesylate
Gemifloxacin may increase the QTc-prolonging activities of Artemether.
Gestodene
The serum concentration of Gestodene can be decreased when it is combined with Artemether.
Goserelin
Goserelin may increase the QTc-prolonging activities of Artemether.
Granisetron
Granisetron may increase the QTc-prolonging activities of Artemether.
Halofantrine
The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Artemether.
Haloperidol
Haloperidol may increase the QTc-prolonging activities of Artemether.
Halothane
The metabolism of Halothane can be decreased when combined with Artemether.
Histrelin
Histrelin may increase the QTc-prolonging activities of Artemether.
Hydrocodone
The metabolism of Hydrocodone can be decreased when combined with Artemether.
HYDROCODONE POLISTIREX
The metabolism of Hydrocodone can be decreased when combined with Artemether.
Hydromorphone
The metabolism of Hydromorphone can be decreased when combined with Artemether.
Hydroxychloroquine
The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether.
Hydroxyzine
Hydroxyzine may increase the QTc-prolonging activities of Artemether.
Hypoxis hemerocallidea root extract
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with St. John's Wort resulting in a loss in efficacy.
Ibandronate
Ibandronate may increase the QTc-prolonging activities of Artemether.
Ibandronic Acid
Ibandronate may increase the QTc-prolonging activities of Artemether.
Ibrutinib
The metabolism of Ibrutinib can be decreased when combined with Artemether.
Ibutilide
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Artemether.
Idarubicin
The metabolism of Idarubicin can be decreased when combined with Artemether.
Idelalisib
The metabolism of Artemether can be decreased when combined with Idelalisib.
Iloperidone
The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Artemether.
Imatinib
The metabolism of Artemether can be decreased when combined with Imatinib.
Imipramine
Imipramine may increase the QTc-prolonging activities of Artemether.
Inamrinone
The therapeutic efficacy of Artemether can be increased when used in combination with Amrinone.
Indacaterol
Indacaterol may increase the QTc-prolonging activities of Artemether.
Indapamide
Indapamide may increase the QTc-prolonging activities of Artemether.
Indinavir
The metabolism of Artemether can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Artemether can be decreased when combined with Indinavir.
Ipratropium Bromide
The metabolism of Ipratropium bromide can be decreased when combined with Artemether.
Ipratropium Bromide Anhydrous
The metabolism of Ipratropium bromide can be decreased when combined with Artemether.
Irbesartan
The metabolism of Artemether can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Artemether can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Artemether can be decreased when combined with Isavuconazonium.
Isoflurane
Isoflurane may increase the QTc-prolonging activities of Artemether.
Isoniazid
The metabolism of Artemether can be decreased when combined with Isoniazid.
Isradipine
Isradipine may increase the QTc-prolonging activities of Artemether.
Itraconazole
The metabolism of Artemether can be decreased when combined with Itraconazole.
Ivabradine
Artemether may increase the QTc-prolonging activities of Ivabradine.
Ivacaftor
The serum concentration of Artemether can be increased when it is combined with Ivacaftor.
Ixazomib
The metabolism of Ixazomib can be decreased when combined with Artemether.
Ketoconazole
The metabolism of Artemether can be decreased when combined with Ketoconazole.
Labetalol
The metabolism of Labetalol can be decreased when combined with Artemether.
Lacidipine
The therapeutic efficacy of Artemether can be increased when used in combination with Lacidipine.
Lamotrigine
The therapeutic efficacy of Artemether can be increased when used in combination with Lamotrigine.
Lapatinib
Lapatinib may increase the QTc-prolonging activities of Artemether.
Leflunomide
The metabolism of Artemether can be decreased when combined with Leflunomide.
Lenvatinib
Lenvatinib may increase the QTc-prolonging activities of Artemether.
Lenvatinib Mesylate
Lenvatinib may increase the QTc-prolonging activities of Artemether.
Lercanidipine
The therapeutic efficacy of Artemether can be increased when used in combination with Lercanidipine.
Letermovir
The metabolism of Letermovir can be decreased when combined with Artemether.
Leuprolide
Leuprolide may increase the QTc-prolonging activities of Artemether.
Levetiracetam
The therapeutic efficacy of Artemether can be increased when used in combination with Levetiracetam.
Levodopa
The metabolism of Levodopa can be decreased when combined with Artemether.
Levofloxacin
Levofloxacin may increase the QTc-prolonging activities of Artemether.
Levofloxacin Anhydrous
Levofloxacin may increase the QTc-prolonging activities of Artemether.
Levomilnacipran
The metabolism of Levomilnacipran can be decreased when combined with Artemether.
Levonorgestrel
The serum concentration of Levonorgestrel can be decreased when it is combined with Artemether.
Lidocaine
The metabolism of Lidocaine can be decreased when combined with Artemether.
Lisuride
The metabolism of Lisuride can be decreased when combined with Artemether.
Lithium
Lithium may increase the QTc-prolonging activities of Artemether.
Lithium Cation
Lithium may increase the QTc-prolonging activities of Artemether.
Lomustine
The metabolism of Lomustine can be decreased when combined with Artemether.
Loperamide
The metabolism of Loperamide can be decreased when combined with Artemether.
Lopinavir
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Artemether.
Loratadine
The metabolism of Loratadine can be decreased when combined with Artemether.
Lorcaserin
The metabolism of Lorcaserin can be decreased when combined with Artemether.
Losartan
The metabolism of Losartan can be decreased when combined with Artemether.
Lovastatin
The metabolism of Artemether can be decreased when combined with Lovastatin.
Luliconazole
The serum concentration of Artemether can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Lumacaftor resulting in a loss in efficacy.
Lumefantrine
The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Artemether.
Lynestrenol
The serum concentration of Lynestrenol can be decreased when it is combined with Artemether.
Magnesium Sulfate
The therapeutic efficacy of Artemether can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Artemether can be increased when used in combination with Magnesium sulfate.
Manidipine
The metabolism of Artemether can be decreased when combined with Manidipine.
Maprotiline
Maprotiline may increase the QTc-prolonging activities of Artemether.
Medroxyprogesterone Acetate
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Artemether.
Mefloquine
The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Artemether.
Meperidine
The metabolism of Pethidine can be decreased when combined with Artemether.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Artemether.
Mepirodipine
The therapeutic efficacy of Artemether can be increased when used in combination with Barnidipine.
Mequitazine
The metabolism of Mequitazine can be decreased when combined with Artemether.
Mesoridazine
The serum concentration of Mesoridazine can be increased when it is combined with Artemether.
Mestranol
The serum concentration of Mestranol can be decreased when it is combined with Artemether.
Methadone
Methadone may increase the QTc-prolonging activities of Artemether.
Methamphetamine
The metabolism of Methamphetamine can be decreased when combined with Artemether.
Methotrimeprazine
The metabolism of Artemether can be decreased when combined with Methotrimeprazine.
Methoxyflurane
The metabolism of Methoxyflurane can be decreased when combined with Artemether.
Methsuximide
The therapeutic efficacy of Artemether can be increased when used in combination with Methsuximide.
Methylene blue
The serum concentration of Methylene blue can be increased when it is combined with Artemether.
Methylphenidate
The metabolism of Methylphenidate can be decreased when combined with Artemether.
Methyprylon
The metabolism of Methyprylon can be decreased when combined with Artemether.
Metoclopramide
Metoclopramide may increase the QTc-prolonging activities of Artemether.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Artemether.
Metronidazole
Metronidazole may increase the QTc-prolonging activities of Artemether.
Mexiletine
The metabolism of Mexiletine can be decreased when combined with Artemether.
Mianserin
The metabolism of Mianserin can be decreased when combined with Artemether.
Mibefradil
The therapeutic efficacy of Artemether can be increased when used in combination with Mibefradil.
Midostaurin
The metabolism of Artemether can be decreased when combined with Midostaurin.
Mifepristone
Artemether may increase the QTc-prolonging activities of Mifepristone.
Minaprine
The metabolism of Minaprine can be decreased when combined with Artemether.
Mirabegron
Mirabegron may increase the QTc-prolonging activities of Artemether.
Mirtazapine
Mirtazapine may increase the QTc-prolonging activities of Artemether.
Mitotane
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Mitotane resulting in a loss in efficacy.
Moclobemide
The metabolism of Moclobemide can be decreased when combined with Artemether.
Modafinil
The metabolism of Artemether can be decreased when combined with Modafinil.
Moexipril
Moexipril may increase the QTc-prolonging activities of Artemether.
Moricizine
The serum concentration of Moricizine can be increased when it is combined with Artemether.
Morphine
The metabolism of Morphine can be decreased when combined with Artemether.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Artemether.
Nateglinide
The metabolism of Nateglinide can be decreased when combined with Artemether.
Nebivolol
The serum concentration of Nebivolol can be increased when it is combined with Artemether.
Nefazodone
The metabolism of Artemether can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Artemether can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Artemether can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Artemether can be decreased when it is combined with Nevirapine.
Nicardipine
The metabolism of Artemether can be decreased when combined with Nicardipine.
Nicergoline
The metabolism of Nicergoline can be decreased when combined with Artemether.
Nicotine
The metabolism of Nicotine can be decreased when combined with Artemether.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Artemether.
Nifedipine
The metabolism of Nifedipine can be decreased when combined with Artemether.
Nilotinib
The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Artemether.
Nilvadipine
The therapeutic efficacy of Artemether can be increased when used in combination with Nilvadipine.
Nimesulide
The therapeutic efficacy of Artemether can be increased when used in combination with Nimesulide.
Nimodipine
The therapeutic efficacy of Artemether can be increased when used in combination with Nimodipine.
Nisoldipine
The therapeutic efficacy of Artemether can be increased when used in combination with Nisoldipine.
Nitrendipine
The therapeutic efficacy of Artemether can be increased when used in combination with Nitrendipine.
Nitrofurazone
The metabolism of Nitrofural can be decreased when combined with Artemether.
Norelgestromin
The serum concentration of Norelgestromin can be decreased when it is combined with Artemether.
Norfloxacin
Norfloxacin may increase the QTc-prolonging activities of Artemether.
Norgestimate
The serum concentration of Norgestimate can be decreased when it is combined with Artemether.
Norgestrel
The serum concentration of Norgestrel can be decreased when it is combined with Artemether.
Nortriptyline
Nortriptyline may increase the QTc-prolonging activities of Artemether.
Octreotide
Octreotide may increase the QTc-prolonging activities of Artemether.
Octylonium
The therapeutic efficacy of Artemether can be increased when used in combination with Otilonium.
Ofloxacin
Ofloxacin may increase the QTc-prolonging activities of Artemether.
Olanzapine
Olanzapine may increase the QTc-prolonging activities of Artemether.
Olaparib
The metabolism of Artemether can be decreased when combined with Olaparib.
Olodaterol
Olodaterol may increase the QTc-prolonging activities of Artemether.
Omeprazole
The metabolism of Artemether can be decreased when combined with Omeprazole.
Ondansetron
Ondansetron may increase the QTc-prolonging activities of Artemether.
Opium
The metabolism of Opium can be decreased when combined with Artemether.
Osimertinib
The serum concentration of Artemether can be increased when it is combined with Osimertinib.
Oxycodone
The metabolism of Oxycodone can be decreased when combined with Artemether.
Oxymorphone
The metabolism of Oxymorphone can be decreased when combined with Artemether.
Oxytocin
Oxytocin may increase the QTc-prolonging activities of Artemether.
Palbociclib
The serum concentration of Artemether can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Artemether.
Palonosetron
The metabolism of Palonosetron can be decreased when combined with Artemether.
Panobinostat
The serum concentration of Artemether can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Artemether can be decreased when combined with Pantoprazole.
Paregoric
The metabolism of Morphine can be decreased when combined with Artemether.
Paroxetine
The metabolism of Artemether can be decreased when combined with Paroxetine.
Pasireotide
Pasireotide may increase the QTc-prolonging activities of Artemether.
Pazopanib
Pazopanib may increase the QTc-prolonging activities of Artemether.
Peginterferon Alfa-2b
The serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
Pentamidine may increase the QTc-prolonging activities of Artemether.
Pentobarbital
The metabolism of Artemether can be increased when combined with Pentobarbital.
Perazine
The serum concentration of Perazine can be increased when it is combined with Artemether.
Perflutren
Perflutren may increase the QTc-prolonging activities of Artemether.
Perhexiline
The metabolism of Perhexiline can be decreased when combined with Artemether.
Periciazine
The serum concentration of Propericiazine can be increased when it is combined with Artemether.
Perphenazine
The serum concentration of Perphenazine can be increased when it is combined with Artemether.
Phenacetin
The metabolism of Phenacetin can be decreased when combined with Artemether.
Phenformin
The metabolism of Phenformin can be decreased when combined with Artemether.
Phenobarbital
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenobarbital resulting in a loss in efficacy.
Phenytoin
The serum concentration of Phenytoin can be increased when it is combined with Artemether.
Pimozide
The risk or severity of QTc prolongation can be increased when Pimozide is combined with Artemether.
Pinaverium
The therapeutic efficacy of Artemether can be increased when used in combination with Pinaverium.
Pindolol
The metabolism of Pindolol can be decreased when combined with Artemether.
Piperazine
The metabolism of Piperazine can be decreased when combined with Artemether.
Pipothiazine
The metabolism of Pipotiazine can be decreased when combined with Artemether.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Artemether.
Posaconazole
The metabolism of Artemether can be decreased when combined with Posaconazole.
Prenylamine
The therapeutic efficacy of Artemether can be increased when used in combination with Prenylamine.
Primaquine
The risk or severity of QTc prolongation can be increased when Primaquine is combined with Artemether.
Primidone
The metabolism of Artemether can be increased when combined with Primidone.
Procainamide
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Artemether.
Prochlorperazine
The serum concentration of Prochlorperazine can be increased when it is combined with Artemether.
Progesterone
The absorption of Progesterone can be decreased when combined with Artemether.
Proguanil
The risk or severity of QTc prolongation can be increased when Proguanil is combined with Artemether.
Promazine
Promazine may increase the QTc-prolonging activities of Artemether.
Promethazine
Promethazine may increase the QTc-prolonging activities of Artemether.
Propafenone
The serum concentration of Artemether can be increased when it is combined with Propafenone.
Propofol
Propofol may increase the QTc-prolonging activities of Artemether.
Propranolol
The metabolism of Propranolol can be decreased when combined with Artemether.
Protriptyline
Protriptyline may increase the QTc-prolonging activities of Artemether.
Pseudoephedrine
The metabolism of Pseudoephedrine can be decreased when combined with Artemether.
Pyrimethamine
The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Artemether.
Quazepam
The serum concentration of Artemether can be increased when it is combined with Quazepam.
Quetiapine
The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Artemether.
Quetiapine fumarate
The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Artemether.
Quinacrine
The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Artemether.
Quinidine
The serum concentration of Quinidine can be increased when it is combined with Artemether.
Quinine
The risk or severity of QTc prolongation can be increased when Quinine is combined with Artemether.
Ranitidine
The metabolism of Ranitidine can be decreased when combined with Artemether.
Ranolazine
Ranolazine may increase the QTc-prolonging activities of Artemether.
Remoxipride
The metabolism of Remoxipride can be decreased when combined with Artemether.
Rifabutin
The metabolism of Artemether can be increased when combined with Rifabutin.
Rifampin
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifampicin resulting in a loss in efficacy.
Rifapentine
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifapentine resulting in a loss in efficacy.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Artemether.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Artemether.
Risperidone
Risperidone may increase the QTc-prolonging activities of Artemether.
Ritonavir
The metabolism of Artemether can be decreased when combined with Ritonavir.
Rolapitant
The metabolism of Artemether can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Artemether can be decreased when combined with Ropinirole.
Ropivacaine
The metabolism of Ropivacaine can be decreased when combined with Artemether.
Rotigotine
The metabolism of Rotigotine can be decreased when combined with Artemether.
Rucaparib
The metabolism of Rucaparib can be decreased when combined with Artemether.
Salmeterol
Salmeterol may increase the QTc-prolonging activities of Artemether.
Saquinavir
Saquinavir may increase the QTc-prolonging activities of Artemether.
Saquinavir Mesylate
Saquinavir may increase the QTc-prolonging activities of Artemether.
Sarilumab
The therapeutic efficacy of Artemether can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Artemether.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Artemether.
Secobarbital
The metabolism of Artemether can be increased when combined with Secobarbital.
Sertindole
The metabolism of Sertindole can be decreased when combined with Artemether.
Sertraline
Sertraline may increase the QTc-prolonging activities of Artemether.
Sevoflurane
Sevoflurane may increase the QTc-prolonging activities of Artemether.
Sildenafil
The metabolism of Artemether can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Artemether can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Artemether can be increased when it is combined with Simeprevir.
Simvastatin
The metabolism of Simvastatin can be decreased when combined with Artemether.
Solifenacin
The metabolism of Solifenacin can be decreased when combined with Artemether.
Sorafenib
Sorafenib may increase the QTc-prolonging activities of Artemether.
Sotalol
The risk or severity of QTc prolongation can be increased when Sotalol is combined with Artemether.
ST. JOHN'S WORT EXTRACT
The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with St. John's Wort resulting in a loss in efficacy.
Sucralfate
Sucralfate can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sulfadiazine
The metabolism of Artemether can be decreased when combined with Sulfadiazine.
Sulfadoxine
The risk or severity of QTc prolongation can be increased when Sulfadoxine is combined with Artemether.
Sulfalene
The risk or severity of QTc prolongation can be increased when Sulfametopyrazine is combined with Artemether.
Sulfamethoxazole
Sulfamethoxazole may increase the QTc-prolonging activities of Artemether.
Sulfisoxazole
Sulfisoxazole may increase the QTc-prolonging activities of Artemether.
Sunitinib
The metabolism of Sunitinib can be decreased when combined with Artemether.
synthetic conjugated estrogens, A
The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Artemether.
Tacrolimus
The metabolism of Tacrolimus can be decreased when combined with Artemether.
Tamoxifen
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Artemether resulting in a loss in efficacy.
Tamsulosin
The metabolism of Tamsulosin can be decreased when combined with Artemether.
Tapentadol
The metabolism of Tapentadol can be decreased when combined with Artemether.
Tegaserod
The metabolism of Tegaserod can be decreased when combined with Artemether.
Telaprevir
The metabolism of Artemether can be decreased when combined with Telaprevir.
Telavancin
Telavancin may increase the QTc-prolonging activities of Artemether.
Telithromycin
Telithromycin may increase the QTc-prolonging activities of Artemether.
Terbinafine
The metabolism of Artemether can be decreased when combined with Terbinafine.
Terbutaline
Terbutaline may increase the QTc-prolonging activities of Artemether.
Terbutaline Sulfate
Terbutaline may increase the QTc-prolonging activities of Artemether.
Terfenadine
The metabolism of Terfenadine can be decreased when combined with Artemether.
Tetrabenazine
The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Artemether.
Theophylline
The metabolism of Theophylline can be decreased when combined with Artemether.
Theophylline anhydrous
The metabolism of Theophylline can be decreased when combined with Artemether.
Thiethylperazine
The serum concentration of Thiethylperazine can be increased when it is combined with Artemether.
Thioproperazine
The serum concentration of Thioproperazine can be increased when it is combined with Artemether.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Artemether.
Thiotepa
The metabolism of Artemether can be decreased when combined with Thiotepa.
Thiothixene
Thiothixene may increase the QTc-prolonging activities of Artemether.
Ticagrelor
The metabolism of Artemether can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Artemether can be decreased when combined with Ticlopidine.
Timolol
The metabolism of Timolol can be decreased when combined with Artemether.
Timolol Anhydrous
The metabolism of Timolol can be decreased when combined with Artemether.
Tiotropium
The metabolism of Tiotropium can be decreased when combined with Artemether.
Tipranavir
The metabolism of Artemether can be decreased when combined with Tipranavir.
Tizanidine
Tizanidine may increase the QTc-prolonging activities of Artemether.
Tocilizumab
The serum concentration of Artemether can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Artemether can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The therapeutic efficacy of Artemether can be increased when used in combination with Tolfenamic Acid.
Tolterodine
Tolterodine may increase the QTc-prolonging activities of Artemether.
Topiramate
The metabolism of Artemether can be decreased when combined with Topiramate.
Toremifene
The risk or severity of QTc prolongation can be increased when Toremifene is combined with Artemether.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Artemether.
Tramadol
The therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.
Tranilast
The therapeutic efficacy of Artemether can be increased when used in combination with Tranilast.
Tranylcypromine
The metabolism of Artemether can be decreased when combined with Tranylcypromine.
Trazodone
Trazodone may increase the QTc-prolonging activities of Artemether.
Treprostinil
Treprostinil may increase the QTc-prolonging activities of Artemether.
Trifluoperazine
The serum concentration of Trifluoperazine can be increased when it is combined with Artemether.
Triflupromazine
The serum concentration of Triflupromazine can be increased when it is combined with Artemether.
Trimebutine
The therapeutic efficacy of Artemether can be increased when used in combination with Trimebutine.
Trimeprazine
The serum concentration of Alimemazine can be increased when it is combined with Artemether.
Trimethadione
The therapeutic efficacy of Artemether can be increased when used in combination with Trimethadione.
Trimethoprim
The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Artemether.
Trimipramine
Trimipramine may increase the QTc-prolonging activities of Artemether.
Triptorelin
Triptorelin may increase the QTc-prolonging activities of Artemether.
Umeclidinium
The metabolism of Umeclidinium can be decreased when combined with Artemether.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Artemether.
Valproate
The metabolism of Artemether can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Artemether can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Artemether can be decreased when combined with Valsartan.
Vandetanib
The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Artemether.
Vardenafil
Vardenafil may increase the QTc-prolonging activities of Artemether.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemether.
Venlafaxine
Venlafaxine may increase the QTc-prolonging activities of Artemether.
Verapamil
The metabolism of Artemether can be decreased when combined with Verapamil.
Vilanterol
Vilanterol may increase the QTc-prolonging activities of Artemether.
Vilazodone
The metabolism of Vilazodone can be decreased when combined with Artemether.
Vinblastine
The metabolism of Vinblastine can be decreased when combined with Artemether.
Vinorelbine
The metabolism of Vinorelbine can be decreased when combined with Artemether.
Vinpocetine
The therapeutic efficacy of Artemether can be increased when used in combination with Vinpocetine.
Voriconazole
The metabolism of Artemether can be decreased when combined with Voriconazole.
Vorinostat
Vorinostat may increase the QTc-prolonging activities of Artemether.
Vortioxetine
The metabolism of Vortioxetine can be decreased when combined with Artemether.
Yohimbine
The metabolism of Yohimbine can be decreased when combined with Artemether.
Zafirlukast
The metabolism of Artemether can be decreased when combined with Zafirlukast.
Zalcitabine
The metabolism of Zalcitabine can be decreased when combined with Artemether.
Ziconotide
The therapeutic efficacy of Artemether can be increased when used in combination with Ziconotide.
Ziprasidone
The metabolism of Artemether can be decreased when combined with Ziprasidone.
Zolpidem
The serum concentration of Zolpidem can be increased when it is combined with Artemether.
Zonisamide
The therapeutic efficacy of Artemether can be increased when used in combination with Zonisamide.
Zuclopenthixol
The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Artemether.
